Nexien BioPharma, Inc. (NXEN) financial statements (2021 and earlier)

Company profile

Business Address 4340 E KENTUCKY AVE
GLENDALE, CO 80246
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4811146820   
Cash and cash equivalents4811146820   
Receivables   15   
Prepaid expense6      
Other current assets 1265    
Other undisclosed current assets  100    
Total current assets:5423311835   
Noncurrent Assets
Long-term investments and receivables   100   
Due from related parties   100   
Other undisclosed noncurrent assets   338   
Total noncurrent assets:   438   
TOTAL ASSETS:54233111,272   
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:317458912 2
Accrued liabilities    12 2
Other undisclosed accounts payable and accrued liabilities3174589   
Debt 12     
Due to related parties    60 40
Other undisclosed current liabilities    19707
Total current liabilities:3294589927049
Noncurrent Liabilities
Long-term debt and lease obligation28      
Long-term debt, excluding current maturities28      
Total noncurrent liabilities:28      
Total liabilities:30294589927049
Stockholders' equity
Stockholders' equity attributable to parent, including:24(6)2661,184(92)(70)(49)
Common stock6554222
Additional paid in capital12,19411,58311,5062,883000
Accumulated deficit(10,337)(8,447)(5,776)(1,475)(94)(72)(51)
Other undisclosed stockholders' equity attributable to parent(1,840)(3,148)(5,470)(229)   
Total stockholders' equity:24(6)2661,184(92)(70)(49)
TOTAL LIABILITIES AND EQUITY:54233111,272   

Income statement (P&L) ($ in thousands)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Operating expenses(3,121)(2,672)(4,301)(1,283)(16)(16)(47)
Other operating expense, net
(Other Expenses)
    (6)(5)(2)
Other undisclosed operating loss(9,771)      
Operating loss:(12,892)(2,672)(4,301)(1,283)(22)(21)(48)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
2(0)     
Interest and debt expense(1)(0)  (6)(5)(2)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)      
Net loss:(12,891)(2,672)(4,301)(1,283)(28)(26)(50)
Other undisclosed net income attributable to parent9,7680  652
Net loss available to common stockholders, diluted:(3,123)(2,672)(4,301)(1,283)(22)(21)(48)

Comprehensive Income ($ in thousands)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net loss:(12,891)(2,672)(4,301)(1,283)(28)(26)(50)
Comprehensive loss, net of tax, attributable to parent:(12,891)(2,672)(4,301)(1,283)(28)(26)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: